FDA to review Pfizer rheumatoid arthritis drug
(Reuters) - U.S. health regulators have accepted the application for Pfizer Inc's closely watched experimental rheumatoid arthritis drug, the drugmaker said on Tuesday.
The Food and Drug Administration is due to decide on the drug, tofacitinib, in August. Pfizer said it has also submitted an application for tofacitinib to regulatory authorities in Japan.
Tofacitinib is one of Pfizer's most important experimental drugs. An oral medicine, it could provide a more convenient alternative to a lucrative class of injected medicines for rheumatoid arthritis and other inflammatory conditions.
(Reporting by Lewis Krauskopf; Editing by Gerald E. McCormick)
- White House reverses, says Obama met uncle and lived with him during law school
- With song and sadness, South Africans mourn Mandela |
- U.S. television, Twitter, alive with new version of 'Sound of Music'
- Ford leans on global Mustang to burnish overseas image
- RPT-UPDATE 1-Ford leans on global Mustang to burnish overseas image
Revered by millions as a beacon of hope against oppression and as an archetype of reconciliation, Nelson Mandela leaves behind a grieving nation. Video